Construction and characterization of a recombinant human adenovirus type 3 vector containing two foreign neutralizing epitopes in hexon

Virus Research

Volumn 183, Issue , 2014, Pages 67-74

  Xue, Chunyan ^a   Tian, Xingui ^a   Li, Xiao ^a   Zhou, Zhichao ^a   Su, Xiaobo ^b   Zhou, Rong ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Ad vector; Epitope display; Hypervariable region; Immune response

Indexed keywords

ADENOVIRUS VECTOR; ENHANCED GREEN FLUORESCENT PROTEIN; EPITOPE; GLUTATHIONE TRANSFERASE; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; RECOMBINANT HUMAN ADENOVIRUS TYPE 3 VECTOR; SP55 PEPTIDE; SP70 PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL GROWTH; CONTROLLED STUDY; ENTEROVIRUS 71; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEP 2 CELL; HOMOLOGOUS RECOMBINATION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOBLOTTING; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THERMOSTABILITY; VERO CELL; VIRUS NEUTRALIZATION;

AD VECTOR; EPITOPE DISPLAY; HYPERVARIABLE REGION; IMMUNE RESPONSE;

ADENOVIRUSES, HUMAN; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; DRUG CARRIERS; ENTEROVIRUS A, HUMAN; EPITOPES; FEMALE; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 84896306586     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2014.01.027     Document Type: Article

References (26)

1. Aguilar L.K., Guzik B.W., Aguilar-Cordova E. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J. Cell Biochem. 2011, 112(8):1969-1977.
2. Crawford-Miksza L., Schnurr D.P. Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J. Virol. 1996, 70(3):1836-1844.
3. Crompton J., Toogood C.I., Wallis N., Hay R.T. Expression of a foreign epitope on the surface of the adenovirus hexon. J. Gen. Virol. 1994, 75(Pt 1):133-139.
4. Gall J.G., Crystal R.G., Falck-Pedersen E. Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype. J. Virol. 1998, 72(12):10260-10264.
5. Krause A., Joh J.H., Hackett N.R., Roelvink P.W., Bruder J.T., Wickham T.J., Kovesdi I., Crystal R.G., Worgall S. Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. J. Virol. 2006, 80(11):5523-5530.
6. Li J., Lad S., Yang G., Luo Y., Iacobelli-Martinez M., Primus F.J., Reisfeld R.A., Li E. Adenovirus fiber shaft contains a trimerization element that supports peptide fusion for targeted gene delivery. J. Virol. 2006, 80(24):12324-12331.
7. Mathis J.M., Bhatia S., Khandelwal A., Kovesdi I., Lokitz S.J., Odaka Y., Takalkar A.M., Terry T., Curiel D.T. Genetic incorporation of human metallothionein into the adenovirus protein IX for non-invasive SPECT imaging. PLoS One 2011, 6(2):e16792.
8. Matthews Q.L. Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach. Mol. Pharm. 2010, 8(1):3-11.
9. Matthews Q.L., Yang PingAr, Wu Qi, Belousova Natalya, Rivera Angel A., Stoff-Khalili Mariam A., Waehler Reinhard, Hsu Hui-Chen, Zan Li, Jing Li, Mountz John D., Wu Hongju, Curiel David T. Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol. J. 2008, 5:98.
10. Matthews Q.L., Fatima A., Tang Y., Perry B.A., Tsuruta Y., Komarova S., Timares L., Zhao C., Makarova N., Borovjagin A.V., Stewart P.L., Wu H., Blackwell J.L., Curiel D.T. HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach. PLoS One 2010, 5(7):e11815.
11. McConnell M.J., Danthinne X., Imperiale M.J. Characterization of a permissive epitope insertion site in adenovirus hexon. J. Virol. 2006, 80(11):5361-5370.
12. Olugbile S., Villard V., Bertholet S., Jafarshad A., Kulangara C., Roussilhon C., Frank G., Agak G.W., Felger I., Nebie I., Konate K., Kajava A.V., Schuck P., Druilhe P., Spertini F., Corradin G. Malaria vaccine candidate: design of a multivalent subunit alpha-helical coiled coil poly-epitope. Vaccine 2011, 29(40):7090-7099.
13. Pandey A., Singh N., Vemula S.V., Couetil L., Katz J.M., Donis R., Sambhara S., Mittal S.K. Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine. PLoS One 2012, 7(3):e33428.
14. Roberts D.M., Nanda A., Havenga M.J., Abbink P., Lynch D.M., Ewald B.A., Liu J., Thorner A.R., Swanson P.E., Gorgone D.A., Lifton M.A., Lemckert A.A., Holterman L., Chen B., Dilraj A., Carville A., Mansfield K.G., Goudsmit J., Barouch D.H. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006, 441(7090):239-243.
15. Rux J.J., Kuser P.R., Burnett R.M. Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods. J. Virol. 2003, 77(17):9553-9566.
16. Schagen F.H., Ossevoort M., Toes R.E., Hoeben R.C. Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion. Crit. Rev. Oncol. Hematol. 2004, 50(1):51-70.
17. Shao J.J., Wong C.K., Lin T., Lee S.K., Cong G.Z., Sin F.W., Du J.Z., Gao S.D., Liu X.T., Cai X.P., Xie Y., Chang H.Y., Liu J.X. Promising multiple-epitope recombinant vaccine against foot-and-mouth disease virus type O in swine. Clin. Vaccine Immunol. 2010, 18(1):143-149.
18. Shiratsuchi T., Rai U., Krause A., Worgall S., Tsuji M. Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice. J. Clin. Invest. 2010, 120(10):3688-3701.
19. Tian X., Su X., Li X., Li H., Li T., Zhou Z., Zhong T., Zhou R. Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon. PLoS One 2012, 7(7):e41381.
20. Wang C., You A., Tian X., Zhao M., Chen Y., Lin T., Zheng J., Xiao M., Zhang Y., Kuang L., Zhou Z., Zhu B. Analysis and solution of false-positives when testing CVA16 sera using an antibody assay against the EV71 virus. Virus Res. 2013, 176(1-2):33-36.
21. Worgall S., Krause A., Qiu J., Joh J., Hackett N.R., Crystal R.G. Protective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF. J. Virol. 2007, 81(24):13801-13808.
22. Wu H., Dmitriev I., Kashentseva E., Seki T., Wang M., Curiel D.T. Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J. Virol. 2002, 76(24):12775-12782.
23. Wu H., Han T., Belousova N., Krasnykh V., Kashentseva E., Dmitriev I., Kataram M., Mahasreshti P.J., Curiel D.T. Identification of sites in adenovirus hexon for foreign peptide incorporation. J. Virol. 2005, 79(6):3382-3390.
24. Zaiss A.K., Machado H.B., Herschman H.R. The influence of innate and pre-existing immunity on adenovirus therapy. J. Cell Biochem. 2009, 108(4):778-790.
25. Zhang Q., Su X., Seto D., Zheng B.J., Tian X., Sheng H., Li H., Wang Y., Zhou R. Construction and characterization of a replication-competent human adenovirus type 3-based vector as a live-vaccine candidate and a viral delivery vector. Vaccine 2009, 27(8):1145-1153.
26. Zhong T., Li X., Zhou Z., Li T., Tian X., Zhou R. Characterization of malleability and immunological properties of human adenovirus type 3 hexon hypervariable region 1. Arch. Virol. 2012, 157(9):1709-1718.